ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Expanding use of potent HIV therapies will limit infections and AIDS

  [ 64 votes ]   [ Discuss This Article ]
www.ProHealth.com • August 8, 2000


Expanding the use of the most potent anti-retroviral drug therapies would help limit new HIV infections and AIDS deaths among gay men in San Francisco over the next ten years even if drug resistance and dangerous sexual behavior soar, according to a new mathematical model developed by scientists at UC San Francisco.

Increased risky behavior always will cause infection and death rates to rise but, contrary to what some in the field have predicted, the new model projects a consistently better future if advanced anti-retroviral therapy is extended to more HIV-infected gay men.

"It's a complex interaction, but a simple outcome, really," says Sally Blower, PhD, associate professor of medicine, microbiology and immunology at UC San Francisco and lead author of a report on the study. "The more you treat, the better you will do, even if risk behavior and drug resistance go way up."

In the model's worst-case projection -- with risk behavior doubling and drug resistance severely diluting the therapy's effectiveness -- infection rates and deaths would still be lower after ten years than if treatment were not expanded.

The report, by a team of UCSF virologists and mathematical biologists, is published in the January 28, 2000 issue of the journal Science.

About half of the HIV-infected men in San Francisco are taking a combination of anti-retroviral drugs, in a treatment regime known as Anti Retroviral Therapy (ART) or Highly Active Anti Retroviral Therapy (HAART), the authors note. Since treated men are likely to retain some degree of infectivity, some AIDS experts have warned that expanding ART treatment could lead to an increased infection rate.

In addition, drug-resistant HIV strains have already emerged and risky sexual behavior has begun to increase in San Francisco. These trends have led some to conclude that expanding use of the advanced ART or HAART therapy - particularly to those less prone to practice safe sex or to follow the difficult drug regimen carefully - would lead to increases in drug resistance, higher HIV infection rates and soaring AIDS deaths.

The new model shows otherwise. "Our model found that over ten years, expanding ART treatment in San Francisco will reduce HIV incidence rates and AIDS death rates below what they would be without expanded treatment," Blower stresses.

Although the model finds a beneficial effect of expanded drug treatment, it starkly reveals that increased risk behavior always leads to more infections and more AIDS deaths.

"Our predictions clearly show that expanding use of viral suppressing drugs to more gay men will always reduce HIV incidence and save lives compared to not expanding treatment, no matter what the rate of drug resistance or risk behavior is," Blower says. "But even small changes in risk behavior will reduce the benefits in the short run. Doubling of risky sexual behavior will negate benefits in the short run and limit them in the long term."

"Our results indicate it is imperative that bath houses not be re-opened and that people practice protected sex, particularly those who are on treatment," she added.

Co-author on the paper is Robert Grant, MD, assistant professor of medicine at UCSF and an AIDS specialist at the Gladstone Institute of Virology and Immunology. Hayley Gershengorn, a former research assistant in Blower's lab and now a Harvard medical student, is also a co-author.
Blower and colleagues developed the model to help AIDS experts assess drug treatment strategies given the high degree of uncertainty in future rates of drug resistance and risky sexual behavior as well as the effectiveness of treatment on both rates of infectivity and long-term survival. It is the first such model to project long-term drug effectiveness while incorporating so many types of uncertainty.

"We used the model to predict the unpredictable," Blower says. The model includes the potential effects of ART on the transmission dynamics of both drug-sensitive and drug-resistant HIV strains. It examines both a "best-case condition" (10 percent annual rate of emergence of resistance; no increase in risky behavior) and a "worst-case condition" (up to 60 percent of cases become drug resistant per year; risky sexual behavior doubles).

Reflecting the range of possible outcomes provided by the model, the Science paper is titled "A Tale of Two Futures: HIV and Anti-Retroviral Therapy in San Francisco."

The model identifies which factors affect how well anti-retroviral therapy works, and uses these factors to suggest how to ensure that the outcome is "the best of times," rather than "the worst of times," Blower points out. The key factor is the rate of risky sexual behavior.

Blower, Gershengorn and Grant have applied what is currently known about HIV biology and infectivity to knowledge of viral transmission and survival generally to develop the new mathematical model.

"We must move the study of epidemics beyond description to make it a predictive science," says Blower. "This is the only certain way to improve strategies to fight infectious diseases."
Grant cautions that although the researchers have used all available information, at this point there are only three years of data on the use of ART and the possibility of viruses becoming resistant to it.

In addition, he says, "the model indicates that relative virulence and transmissibility of HIV are critical determinants in predicting the epidemic behavior of a drug-resistant virus. More information on these two factors will be crucial in the coming years."

The research is funded by the National Institute of Allergies and Infectious Diseases, part of the National Institutes of Health.



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength FibroSleep™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map